APOLLOMICS INC (APLM)
KYG0411D1079 - Common Stock
Overall APLM gets a fundamental rating of 1 out of 10. We evaluated APLM against 565 industry peers in the Biotechnology industry. APLM may be in some trouble as it scores bad on both profitability and health. APLM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
APLM had negative earnings in the past year.
APLM had a negative operating cash flow in the past year.
1.2 Ratios
Looking at the Return On Assets, with a value of -311.63%, APLM is doing worse than 94.66% of the companies in the same industry.
With a Return On Equity value of -418.59%, APLM is not doing good in the industry: 78.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -311.63% | ||
| ROE | -418.59% | ||
| ROIC | N/A |
ROA(3y)-104.14%
ROA(5y)N/A
ROE(3y)-139.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, APLM has more shares outstanding
Compared to 1 year ago, APLM has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -25.21, we must say that APLM is in the distress zone and has some risk of bankruptcy.
APLM has a worse Altman-Z score (-25.21) than 89.68% of its industry peers.
APLM has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
APLM's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. APLM outperforms 45.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.21 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
The Current ratio of APLM (2.95) is worse than 65.84% of its industry peers.
A Quick Ratio of 2.95 indicates that APLM has no problem at all paying its short term obligations.
APLM has a Quick ratio of 2.95. This is in the lower half of the industry: APLM underperforms 63.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.95 |
3. Growth
3.1 Past
APLM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3757.18%.
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
APLM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.80% yearly.
Based on estimates for the next years, APLM will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y99.53%
EPS Next 2Y41.2%
EPS Next 3Y25.8%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-23.3%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APLM. In the last year negative earnings were reported.
Also next year APLM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APLM's earnings are expected to grow with 25.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3Y25.8%
5. Dividend
5.1 Amount
APLM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APOLLOMICS INC
NASDAQ:APLM (12/20/2024, 8:00:00 PM)
After market: 9.24 -0.51 (-5.23%)9.75
+0.38 (+4.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.34%
Inst Owner ChangeN/A
Ins Owners21.56%
Ins Owner ChangeN/A
Market Cap10.72M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.26 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.93
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-39.29
FCFYN/A
OCF(TTM)-39.28
OCFYN/A
SpS0
BVpS37.49
TBVpS24.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -311.63% | ||
| ROE | -418.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-104.14%
ROA(5y)N/A
ROE(3y)-139.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.9% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.95 | ||
| Altman-Z | -25.21 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3757.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y99.53%
EPS Next 2Y41.2%
EPS Next 3Y25.8%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-23.3%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-9748.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.95%
EBIT Next 3Y-31.17%
EBIT Next 5YN/A
FCF growth 1Y-4810.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4810.11%
OCF growth 3YN/A
OCF growth 5YN/A